期刊文献+

地昔帕明单用和合用替尼泊苷对大鼠脑胶质瘤C6细胞增殖的调控作用 被引量:5

Effect of desipramine alone and in combination with teniposide on proliferation in rat C6 glioma cells
下载PDF
导出
摘要 目的 :研究三环类抗抑郁药地昔帕明 (DMI)对脑胶质瘤C6细胞增殖的调控作用 ,并探讨与临床常用治疗脑瘤的化疗药物替尼泊苷 (VM 2 6 )合用的协同效应。方法 :采用MTT比色法测定大鼠脑胶质瘤C6细胞增殖抑制作用和流式细胞术 (FCM)进行细胞周期分析。结果 :DMI (10— 80 μmol/L)对C6细胞的增殖具有明显的抑制作用 ,呈浓度时间依赖关系 ,药物作用 2 4h的IC50 (95 %置信区间 )为 2 0 7(17 3— 2 4 2 ) μmol/L。DMI (2 0 μmol/L)可使G0 -G1期细胞增加 (P <0 0 5 )而S期细胞减少 (P <0 0 5 ) ,G2 期细胞则无改变。不同浓度DMI和VM 2 6合用显示明显协同效应 (Q =0 72 )。结论 :DMI体外对C6细胞增殖具有浓度时间依赖性抑制作用 ,使细胞阻滞于G0 -G1期 ;与VM 2 Purpose:To study the antiproliferative effect of tricyclic antidepressant desipramine(DMI) alone or in combination with chemotherapeutic agent teniposide (VM 26) against rat C6 glioma cells.Methods:Inhibition of proliferation was measured using MTT colorimetric assay and cell cycle distribution was analysed by flow cytometry(FCM). Results:DMI (10—80?μmol/L) suppressed C6 cell proliferation in a concentration and time dependent manner.The IC 50 and 95% confidence interval were 20.7(17.3—24.2)?μmol/L after 24?h treatment with DMI.DMI(20?μmol/L) significantly increased the proportion of G 0—G 1 phase cells, concomitant with a decrease in the proportion of S phase cells. The combined DMI with VM 26 produced significant synergic antiproliferative effect (combination index Q=0.72). Conclusions:The results indicate DMI could lead to inhibition of C6 cell proliferation and arrest in G 0—G 1 phase of cell cycle, and synergize chemotherapeutic action with VM 26 against C6 glioma cells.
出处 《中国癌症杂志》 CAS CSCD 2000年第1期62-64,共3页 China Oncology
基金 上海市教委博士课题科研基金项目 !(编号 :970 0 2 )
关键词 地昔帕明 替尼泊苷 脑胶质瘤 C6细胞 大鼠 desipramine teniposide glioma cell cycle drug synergism
  • 相关文献

参考文献7

二级参考文献48

共引文献24

同被引文献27

  • 1张伟,江涛,袁芳,李桂林,董丽萍,徐立新,韩明,崔云.脑胶质瘤组织培养化疗药物敏感性的研究[J].中国微侵袭神经外科杂志,2007,12(4):163-166. 被引量:16
  • 2Nakagawa H,Fujita T,Kubo S,et al.Differrence in CDDP penetration into CSf between selective intraarterial chemotherapy in patients with malignant glioma and tntravenous or intracarotid administration in patients with metastatic brain tumor.Cancer Chemother Pharmacol,1996,37(4):317 -326
  • 3Demeule M,Shedid D,Beaulieu E.Expression of multidrug-resistance P glycoprotein(p-gp) in human brain tumors.[J].Int J Cancer,2001,93:62-66
  • 4Hargravc DR, Zacharoulis S. Pediatric CNS tumors: current treatment and future directions [ J] . Expert Rev Neurother,2007,7 (8) : 1029 - 1042.
  • 5Hand CM, Vender JR, Black P. Chemotherapy in experimental brain tumor, part I : invitro colorimetrie MTT assay [ J ]. J Neurooncol, 1998,36(1) :1 -6.
  • 6Demeule M, Shedid D, Beaulieu E. Expression of muhidrug - resist- ance P glycoprotein( p -gp) in human brain tumors[ J] . Int J Canc- er,2001,93:62 - 66.
  • 7Vanden Bent M J, Hegi ME,Stupp R. Recent developm entsin the use of chemotherapy in brain tumours[ J] . Eur J Cancer,2006,42 (5) : 582 -588.
  • 8Nikkhab G ,Tonn JC, Hoffmann O ,et al. The MTT assay for chemosen- sitivity testing of human tumors of the central nervous system, part 11 : evaluation of patient and drug- specific variable[ J]. J Neuro Oncol, 1992,13(1) :13 -24.
  • 9Rampling R, James A, Papanastassiou V. The present and future management of malignant brain tumours : surgery, radiotherapy, chem- otherapy[ J ]. J Neurol Neurosurg Psychiatry, 2004,75 Suppl 2 : 1124 -30.
  • 10Grundy RG, Wilne SH, Robinson KJ. Primary postoperative chemo- therapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/ SIOP CNS 9204 trial[ J]. Ear J Cancer,2010,46( 1 ) :120- 133.

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部